Navigation Links
Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854
Date:1/9/2014

gton's chorea, schizophrenia, Tourette's syndrome, and tardive dystonia.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a clinical stage drug discovery company primarily focused on neurological and endocrine based diseases and disorders.  The Company discovers and develops innovative pharmaceuticals, in diseases with high unmet medical needs or where the existing drug classes are inadequate, through a disciplined yet entrepreneurial process.  Utilizing a portfolio approach to drug discovery, Neurocrine has multiple small molecule drug candidates at various stages of pharmaceutical development.  Neurocrine's two lead late stage clinical programs are elagolix, a GnRH antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned VMAT2 inhibitor for the treatment of movement disorders.  Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's VMAT2 program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's VMAT2 program include, but are not limited to; risk that NBI-98854 will not proceed to later stage clinical trials and risk that the Company's clinical trials will fail to demonstrate that NBI-98854 is safe and effective. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates;
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
2. Neurocrine Biosciences Reports First Quarter 2012 Results
3. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
4. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2012 Financial Results
5. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
7. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
8. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
9. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
10. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
11. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014 In today,s increasingly ... web presence to reflect the needs of a ... must meet the needs of key stakeholders while ... According to recent research by benchmarking ... the participating companies averaged more than $100,000 in ...
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. , Dec. ... SRNE ;  Sorrento), an oncology company developing ... Conkwest, Inc., a privately-held immuno-oncology company developing proprietary ... cell-line based therapy, announced today that the companies ... develop next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies ...
(Date:12/19/2014)... 18, 2014 Research and Markets ... the "Micro Market Monitor: North American Dermatology ... http://photos.prnewswire.com/prnh/20130307/600769 ... steadily, which has resulted in fueling the overall ... main purpose of these dermatology devices is to ...
Breaking Medicine Technology:Building a Best-in-Class Pharma Global Brand Website 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3
(Date:12/21/2014)... 21, 2014 Hundreds of Byetta ... claims involving a class of Type 2 diabetes ... forward in a federal multidistrict litigation now underway ... Bernstein Liebhard LLP reports. According to an Order ... data cut-off date of February 27, 2014 for ...
(Date:12/21/2014)... Muskegon, Mi (PRWEB) December 21, 2014 ... a child in need while at the same time helping ... is a non-profit community-based organization committed to serving those ... to meet their needs to improve the quality of life. ... would make an impact in the local community and he ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 SCI ... of the issues and systemic barriers for disabled athletes ... Paratriathlon Champion. Scheidies has a condition called juvenile macular ... He describes how he adapted his athletic ambitions to ... his success in triathlon to pioneer the way for ...
(Date:12/21/2014)... 2014 The Oncology Institute of Hope and ... Ana and Whittier offices. The Hope for the Holidays Toy ... patients and their families during the holiday season. This year, ... 70 children between both offices. This event continues to be ... community service team, store managers and assistant managers came out ...
(Date:12/20/2014)... (PRWEB) December 21, 2014 MissyDress, a ... for all prom lovers. The business has drastically cut ... prom dresses to everyone until Jan. 30, 2015. Many ... dresses, sweetheart dresses, V-neck dresses, lace dresses, and more. ... are not there every day. Whether A-line princess prom ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2
... Serena Gordon HealthDay Reporter , WEDNESDAY, June 8 ... birth control at the same time they,re having a uterine ... to get one compared to women offered one later on, ... the expulsion rate for IUDs inserted immediately after a uterine ...
... Steven Reinberg HealthDay Reporter , WEDNESDAY, June 8 ... Wednesday called for a label warning on the popular statin ... when taken in the highest doses. This risk has ... (simvastatin) a day, particularly during the first year of treatment, ...
... innovative use of "pay-for-performance" bonuses to try to reduce racial ... turned up no evidence of the problem at any of ... that raises questions about the effectiveness of the state,s novel ... of Health Affairs (June 9, 2011), found that ...
... more widespread than was previously realised, research suggests. Blood samples ... of the H1N1 flu season showed that almost half were carrying ... cent who tested positive had contracted swine flu, although some had ... vaccinated. The research, led by the University of Edinburgh, ...
... PORTLAND, Ore. Women who receive a contraceptive known as ... abortion experience few complications and are less likely to have ... by several weeks, according to a new study at Oregon ... in the June 9 New England Journal of Medicine ...
... , WEDNESDAY, June 8 (HealthDay News) -- Brain scans that detect ... States as soon as this year, researchers reported this week, though ... much help for those with the disease. "You,ll ... to people who want to know what,s going on when their ...
Cached Medicine News:Health News:It's Safe to Get IUD Right After Abortion, Miscarriage: Study 2Health News:It's Safe to Get IUD Right After Abortion, Miscarriage: Study 3Health News:FDA Places New Warning Label on Zocor 2Health News:FDA Places New Warning Label on Zocor 3Health News:Pioneering hospital pay-for-performance program falls short of its goals 2Health News:Immediate use of an IUD following abortion more likely to prevent unintended pregnancies 2Health News:Brain Scans to Spot Alzheimer's May Be Available This Year 2
An easy-to-fit high water content spherical soft lens manufactured using cast molding technology, and designed for use in the correction of myopia on a daily wear or extended wear basis....
... With the Hertel, the ... hands and held firmly against ... line with the center of ... against the two temporal orbital ...
Hertel exophthalmometer is used for precise exophthalmos measurements (e.g. exophthalmic goiter)....
Naugle exophthalmometer is superior and inferior orbital rim-based instrument....
Medicine Products: